GCM
SAGE

Gladius Capital Management’s Sage Therapeutics SAGE Stock Holding History

Gladius Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-539
Closed -$18K – 485
2022
Q2 		$18K Buy
+539
New +$18.1K ﹤0.01% 322

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Gladius Capital Management's SAGE Position: Q3 2022 in Review

Gladius Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2022, closing a stake of 539 shares — an estimated $18K sold.

Gladius Capital Management first reported a position in SAGE in Q2 2022 and held it in 1 quarter. The position peaked at $18K in Q2 2022. 200 funds tracked by Wall St. Rank hold SAGE as of Q3 2022.

  • Gladius Capital Management reported no remaining Sage Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Gladius Capital Management sold 539 Sage Therapeutics shares in Q3 2022, an estimated $18K.
  • Gladius Capital Management first reported a position in Sage Therapeutics in Q2 2022 and held it in 1 quarter.
  • Gladius Capital Management's Sage Therapeutics position peaked at $18K in Q2 2022.
  • 200 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2022.

Based on Gladius Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.